NEWS RELEASE: BioInteractions Launches Surface-Active Systems – A New Standard in Long Term Medical Device Performance
New category of innovative biocompatible coating solutions, Surface Active Systems, provides improved implant performance, superior interventional results and enhanced quality of life.
[Photo courtesy of BioInteractions]
“For many clinicians and patients, the benefits of Surface-Active Systems coatings remain largely unknown,” explains Nicholas Inston, President-Elect of the Vascular Access Society and Consultant Surgeon in Vascular Access & Transplantation at Queen Elizabeth Hospital Birmingham. “By preventing infection and reducing clot formation at the device surface, these coatings address two of the most serious risks associated with dialysis catheter use: bloodstream infections and thrombosis—including thrombin sheath formation, a common cause of catheter dysfunction and reduced dialysis efficiency.
“Providing long-lasting, site-specific antimicrobial and thromboresistant protection— with the potential to reduce reliance on systemic drugs—has the potential to transform how vascular access is managed in dialysis,” adds Inston. “In addition, by reducing the need for systemic antibiotics, minimising interventions, preventing fibrin sheath development, and lowering hospital readmissions, these coatings could help reshape clinical strategies, ease the burden on healthcare systems, and give patients greater safety and control over their care.”
“Surface-Active Systems represent a paradigm shift for medical device coating technologies,” explains Arjun Luthra, Commercial Director at BioInteractions. “Within this category, durable surface treatments are tailored to enhance patient outcomes through improved device longevity as well as increased device efficacy, with better safety of medical devices. Patients benefit from improved implant performance, superior interventional results and an enhanced quality of life. Overall, they are suitable for a wide variety of medical devices and are compatible with a broad range of device geometries and substrates ranging from small metal implants to larger polymer-based systems.”
Within the Surface-Active Systems category are two product families: Surface-Active Therapeutics and Surface-Active Materials.
Surface-Active Therapeutics, which includes AstutePlus® Antithrombogenic and TridAnt® Antimicrobial, are advanced surface treatment technologies that do not need to release active ingredients to be effective. Instead, they remain permanently functional on the device surface providing sustained therapeutic performance without systemic drug exposure. Applied directly to the surface of medical devices, these treatments address clinical challenges such as infection, thrombosis and fibrin sheath formation.
Surface-Active Materials, which includes Assist™ Lubricious, are robust, durable surface treatments that enhance device performance, particularly in demanding environments where friction and movement, such as in tortuous environments, are critical factors to the device insertion, removal and performance in the patient. These surface treatments improve the physical function of the surface, enhance the biocompatibility as well as strengthens the mechanical durability of the devices, ensuring consistent operation over time and in high-stress conditions.
“For over three decades, BioInteractions has been at the forefront of biocompatible innovations, delivering advanced solutions like TridAnt®, an enhanced antimicrobial coating that is the only non-leaching antimicrobial coating in the world; as well as AstutePlus®, an Advanced Antithrombogenic Coating; and Assist™, a Flexible Hydrophilic Coating, that address clinical challenges with unmatched precision, performance and durability,” concludes Luthra. “With Surface-Active Systems, BioInteractions is setting a new benchmark in medical device coatings, offering OEMs permanent performance on their devices whilst reducing the risks of systemic drug-based therapies. It’s the next leap forward in better, safer and smarter implants.”
For more information about BioInteractions’ portfolio of coatings, click here: https://biointeractions.com/.
About BioInteractions
BioInteractions Ltd has over 30 years of heritage in research and development, specialising in biocompatible material technologies for the worldwide medical device industry.
Based in purpose-built laboratories in the Thames Valley Science Park at the University of Reading, the company develops advanced and specialised coatings for devices used in medical treatments and procedures ranging from class 1 to class 3 implants. BioInteractions has been a critical supplier to the medical device industry for over 30 years and supported key medical device manufacturers with their innovative solutions. The portfolio of innovative materials confronts chronic challenges such as thrombus formation, infections, friction and various other biocompatible challenges faced by our partners.
BioInteractions has secured long-term partnerships with major medical device manufacturers around the world and, in 2002, won the Queen’s Award for Enterprise for a biocompatible coating that was the first to combine multiple elements for enhanced long-term antithrombogenic activity for all materials and shapes in just one
The opinions expressed in this news release are the author’s only and do not necessarily reflect those of Medical Design & Outsourcing or its employees.
